Literature DB >> 6578531

Brain purinergic activity linked with depressive symptomatology: hypoxanthine and xanthine in CSF of patients with major depressive disorders.

H Agren, F Niklasson, R Hällgren.   

Abstract

The purine metabolites hypoxanthine and xanthine were analyzed in cerebrospinal fluid (CSF) of 70 patients with major depressive disorders (diagnosed according to Research Diagnostic Criteria) and, for reference, in 26 nonpsychiatric individuals. In the patient group, levels adjusted by analysis of covariance to same sex, age, height, and weight were univariately and multivariately correlated with both depressive subdiagnoses and individual depressive symptoms. Results indicate that raw CSF levels in depressed patients are significantly correlated with the four variables used in adjustment (for hypoxanthine mainly negatively with height; for xanthine mainly positively with age). Hypoxanthine and xanthine both appear to be linked with the expression of depressive symptomatology: lower levels of hypoxanthine are associated with anger and suicidal tendencies, and higher levels are related to memory disturbance; lower xanthine levels characterize patients with subjective feelings of depression, and in patients with higher levels appetite is poor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6578531     DOI: 10.1016/0165-1781(83)90042-2

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

Review 1.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

2.  Studies of biochemical markers in cerebrospinal fluid in patients with meningoencephalitis.

Authors:  G Ronquist; T Callerud; F Niklasson; G Friman
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

3.  Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile.

Authors:  Rima Kaddurah-Daouk; Peixiong Yuan; Stephen H Boyle; Wayne Matson; Zhi Wang; Zhao Bang Zeng; Hongjie Zhu; George G Dougherty; Jeffrey K Yao; Guang Chen; Xavier Guitart; Paul J Carlson; Alexander Neumeister; Carlos Zarate; Ranga R Krishnan; Husseini K Manji; Wayne Drevets
Journal:  Sci Rep       Date:  2012-09-19       Impact factor: 4.379

4.  Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.

Authors:  Sudeepa Bhattacharyya; Ahmed T Ahmed; Matthias Arnold; Duan Liu; Chunqiao Luo; Hongjie Zhu; Siamak Mahmoudiandehkordi; Drew Neavin; Gregory Louie; Boadie W Dunlop; Mark A Frye; Liewei Wang; Richard M Weinshilboum; Ranga R Krishnan; A John Rush; Rima Kaddurah-Daouk
Journal:  Transl Psychiatry       Date:  2019-07-04       Impact factor: 6.222

5.  Urinary metabolites as a predictive marker for perinatal depression: A secondary analysis of the mothers, Omega-3 & Mental Health Study.

Authors:  Patricia S Greco; Ashley M Hesson; Ellen Mozurkewich; Deborah R Berman
Journal:  Psychiatry Res Commun       Date:  2022-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.